Mylan Granted Approval for Generic Avalide Tablets
Posted on: Tuesday, 17 June 2008, 09:01 CDT
Mylan has announced that its subsidiary, Mylan Pharmaceuticals, has received tentative approval from the FDA for its abbreviated new drug application for Irbesartan and hydrochlorothiazide tablets, 150mg/12.5mg and 300mg/12.5mg.
Irbesartan and hydrochlorothiazide tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis's Avalide tablets.
Currently, Mylan has 92 abbreviated new drug applications pending FDA approval, 20 of which are potential first-to-file opportunities.
Source: Datamonitor
Related Articles
- Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
- Mylan Wins FDA Approval for Generic Risperdal Tablets
- Mylan Wins Final Approval for Generic Hypertension Drug
- Teva Gets FDA Approval for Generic Norvasc
- Mylan Gets Tentative Approval for Generic Depakote
- Mylan Announces Tentative Approval for Rabeprazole Sodium Delayed-Release Tablets
- Mylan Announces Supply Agreement With Ortho-McNeil on Oxybutynin
- Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP
- Mylan Announces Final FDA Approval for Glimepiride Tablets
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
Rating: 3.3 / 5 (7 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds